Altasciences, an integrated CRO/CDMO offering pharmaceutical and biotechnology companies early stage drug development services, has acquired Sinclair Research, a preclinical CRO.
Sinclair is a nonclinical CRO that provides full-service IND and NDA enabling toxicology and safety pharmacology services. The firm’s services provide support to biopharmaceutical, animal health and medical device development programs. The deal will expand Altascience’s geographic reach as it expands from the East and West coast to establish a presence in the Midwest.
“This acquisition will add significant capacity and expertise to Altasciences’ existing preclinical offering,” said Steve Mason, co-COO at Altasciences. “Sinclair’s experience conducting research on a wide variety of species in a comprehensive range of drug classes will broaden our current preclinical offering and support Altasciences’ focus on providing our clients with customized solutions.”
Fredrikson & Byron P.A. and Goodwin Procter LLP served as legal advisors to Altasciences on the transaction. Fairmount Partners acted as exclusive financial advisors to Sinclair Research, and Troutman Pepper acted as legal counsel.